Maxim Group Initiates Coverage On Medicus Pharma With Buy Rating, Announces Price Target of $10
Medicus Pharma Analyst Ratings
Maxim Group Initiates Medicus Pharma(MDCX.US) With Buy Rating, Announces Target Price $10
Express News | Medicus Pharma Shares Are Trading Higher After the Company Its INAD File No.013880 Was Used as Part of a Major Species Designation From the FDA
Medicus Pharma up 9% in Pre-market Trading as FDA Approves Anti-cancer Patch for Horses
Medicus Pharma Eyes Veterinary Market With FDA Designation
Express News | Medicus Pharma Says INAD File No.013880 Received Minor Use In Major Species Designation From FDA For Its Dissolvable D-MNA To Treat External Squamous Cell Carcinoma In Horses
Medicus Pharma Announcs Its INAD Received MUMS From U.S. FDA
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation From the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
Medicus Pharma Eyes Pivotal Trial for Novel Skin Cancer Therapy as Phase 2 Enrollment Progresses | TSX-V:MDCX, NASDAQ:MDCX
Medicus Pharma Enters Collaboration Agreement With Swanielle
Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region
Medicus Pharma Ltd. Expands With Strategic Takeover
6-K: Report of foreign private issuer (related to financial reporting)
Medicus Pharma Unveils Ex-GSK and Pfizer Senior as Chief Medical Officer | TSX-V:MDCX, NASDAQ:MDCX
Leadership Changes at Medicus Pharma Ltd
Press Release: Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer
US Manufacturing Index Rises To 43, Highest Since 2020
Medicus Pharma Shares Fall After IPO
Medicus Pharma CEO Dr Raza Bokhari on $4M Nasdaq IPO & Phase 2 Trial | TSX-V:MDCX, NASDAQ:MDCX